Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells

Src and the mammalian target of rapamycin (mTOR) signaling are commonly activated in non-small cell lung cancer (NSCLC) and hence potential targets for chemotherapy. Although the combined use of Src inhibitor Dasatinib with other chemotherapeutic agents has shown superior efficacy for cancer treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Bin, Xu, Xin, Luo, Jie, Wang, Heyong, Zhou, Songwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465694/
https://www.ncbi.nlm.nih.gov/pubmed/26061184
http://dx.doi.org/10.1371/journal.pone.0129663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465694/
https://www.ncbi.nlm.nih.gov/pubmed/26061184
http://dx.doi.org/10.1371/journal.pone.0129663

Ejemplares similares